Q-omics provides the consensus-scored RAB1AP2 profile across patient tissues and cancer cell-line models. RAB1AP2 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, RAB1AP2 is differentially expressed in 3, with the highest sampling consensus in PRAD. Additionally, RAB1AP2 RNA expression shows 5,605 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, PRAD, and STAD as cancer lineages where RAB1AP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB1AP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB1AP2 survival associations across molecular data types. RAB1AP2 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB1AP2 RNA expression–survival associations across cancer types. High RAB1AP2 expression shows unfavorable associations in UCEC, DLBC, BLCA, LUAD, LUSC and READ. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UCEC as the clearest survival context for RAB1AP2 RNA expression.
This table summarizes RAB1AP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RAB1AP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB1AP2 shows lower tumor expression in LUSC and higher tumor expression in PRAD and BRCA. The PRAD box plot shows higher RAB1AP2 RNA expression in tumor versus normal tissue (log2 FC = +0.018, t-test p = .014).
This table shows molecular features associated with RAB1AP2 in patient tissues and cancer cell lines. In patient samples, RAB1AP2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
